21 CFR 211.186
Master production and control records.
- Inspections citing it: 581
- Of those classified, ended OAI: 20%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 211.186(a)
- 250 · Written procedures followed
- 211.186(b)(9)
- 216 · Manufacturing Instructions and Specifications
- 211.186(b)(7)
- 47 · Theoretical yield statement including percentages
- 211.186(b)(8)
- 47 · Description of containers, labels, et. al.
- 211.186(b)(4)
- 14 · Variation in the Amount of Components Used
- 211.186(b)(3)
- 7 · Component Name and Code
Regulation Text
eCFR, as of Nov 6, 2026(a) To assure uniformity from batch to batch, master production and control records for each drug product, including each batch size thereof, shall be prepared, dated, and signed (full signature, handwritten) by one person and independently checked, dated, and signed by a second person. The preparation of master production and control records shall be described in a written procedure and such written procedure shall be followed.
(b) Master production and control records shall include:
(1) The name and strength of the product and a description of the dosage form;
(2) The name and weight or measure of each active ingredient per dosage unit or per unit of weight or measure of the drug product, and a statement of the total weight or measure of any dosage unit;
(3) A complete list of components designated by names or codes sufficiently specific to indicate any special quality characteristic;
(4) An accurate statement of the weight or measure of each component, using the same weight system (metric, avoirdupois, or apothecary) for each component. Reasonable variations may be permitted, however, in the amount of components necessary for the preparation in the dosage form, provided they are justified in the master production and control records;
(5) A statement concerning any calculated excess of component;
(6) A statement of theoretical weight or measure at appropriate phases of processing;
(7) A statement of theoretical yield, including the maximum and minimum percentages of theoretical yield beyond which investigation according to § 211.192 is required;
(8) A description of the drug product containers, closures, and packaging materials, including a specimen or copy of each label and all other labeling signed and dated by the person or persons responsible for approval of such labeling;
(9) Complete manufacturing and control instructions, sampling and testing procedures, specifications, special notations, and precautions to be followed.
Recently Cited Sites
Newest inspections citing this section; each opens the site- Spartan Chemical Co IncUnited States · Nov 21, 2025
- Simtra Deutschland GmbHGermany · Sep 26, 2025
- Fareva AmboiseFrance · Sep 16, 2025
- BSO, LLCUnited States · Jun 27, 2025
- Hysan Pharmaceutical Co., Ltd.Unknown · Jun 12, 2025
- Catalent Ontario LimitedCanada · May 2, 2025
- Innocore Sales & Marketing Inc.Canada · Apr 25, 2025
- KVK Tech, Inc.United States · Mar 14, 2025
- Jubilant Cadista PharmaceuticalsUnited States · Jan 15, 2025
- RADIANCE BEAUTY & WELLNESS INC.United States · Apr 17, 2024
- Multaler Et Cie S.A.S.France · Apr 17, 2024
- Qualgen, LLCUnited States · Mar 19, 2024
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR